Inoue T, Kato T, Uchida T, Sakuma M, Nakajima, A, Shibazaki M, Imoto Y, Hikichi Y, Node K. Local release of C-reactive protein from the vulnerable plaque or coronary arterial wall injured by stenting (reply). J Am Coll Cardiol 2006; 47: 1734

Inoue T, Kato T, Hikichi Y, Hashimoto S, Hirase T, Morooka T, Imoto Y, Takeda Y, Sendo F, Node K. Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening. Thromb Haemost 2006; 95: 43-48

Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol 2006; 26: 82-86

Kato T, Inoue T, Yamagishi S, Morooka T, Okimoto T, Node K. Low-density lipoprotein subfractions and the prevalence of silent lacnar infarction in subjects with essential hypertension. Hypertens Res 2006; 29: 303-307

Kato T, Inoue T, Morooka T, Yoshimoto N, Node K. Short-term passive smoking causes endothelial dysfunction via oxidative stress in non smokers. Can J Physiol Pharmacol 2006; 84; 523-529

Inoue T, Hikichi Y, Kato T, Morooka T, Yoshida K, Fujimatsu D, Komoda H, Kameda M, Nonaka M, Hashimoto S, Node K. Comparison of changes in circulating platelet-derived microparticles and platelet surface P-selectin expression after coronary stent implantation. Platelets 2006; 17: 416-420

Wang D, Hirase T, Inoue T, Node K. Atorvastatin inhibits angiotensin II-induced T-type Ca2+ channel expression in endothelial cells. Biochem Byophys Res Commun 2006; 347: 394-400

Ikeda H, Inoue T, Uemura S, Kaihara R, Tanaka H, Node K. Effects of candesartan on post-menopausal symptoms in middle-aged and elderly women with hypertension. Hypertens Res 2006; 29: 1007-1012

Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakao Y. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentration in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006; 55: 1954-1960

Kato T, Ishida S, Morooka T, Inoue T, Node K. Postprandial hyperglycemia is a possible contributor to paroxysmal atrial fibrillation. J Cardiol 2006; 48: 269-272

Inoue T, Node K. Vascular failure -a new clinical entity for vascular disease-. J Hypertens 2006; 24: 2121-2130

Kaneko N, Matsuda R, Nakajima T, Shinozaki M, Ohtani N, Oda K, Hasumi H, Shimamoto K. Norepinephrine-induced diastolic dysfunction with aortic valve opening under calcium-loading in rats. Drug Dev Res 2006; 67: 511-518

Sasayama S, Izumi T, Seino Y, Ueshima K, Asanoi H, Kaneko N, Nakamoto T, Harasawa H, Arikawa T. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. Circ J 2006; 70: 1-7

Hata N，Seino Y，Tsutamoto T，Kaneko N，Hiramitsu S，Yoshikawa T，Yokoyama H，Tanaka K，Mizuno K，Nejima J，Kinoshita M. Effects of carperitide on cardiorenal protection and prognosis in patients with acute decompensated heart failure; PROTECT Study. Circ J 2006; 70: 539

Seino Y，Tsutamoto T，Hata N，Kaneko N，Hiramitsu S，Yoshikawa T，Yokoyama H，Tanaka K, Takagi G，Asai K，Mizuno K，Nejima J，Kinoshita M. Effects of carperitide treatment on cardio-renal biomarkers in patients with acute decompensated heart failure:sub-analyses of the PROTECT Study. Circ J 2006; 70: 451

Matsuda T，Matsuda R，Taguchi I，Toyoda S，Kikuchi M. A novel cardioprotective drug, K201 (JTV519), induces prolongation of QT and QTc intervals,but not torsades de pointes. Dokkyo J Med Sci 2006; 33: 17-24

Nakajima T，Matsuda R，Shinozaki M，Abe S，Suzuki H. Effects of norepinephrine on left ventricular hemodynamics and myocardial blood flow in rats with and without calcium overload. Dokkyo J Med Sci 2006; 33: 35-41

Kaneko N, Matsuda R, Ohtani N, Nakajima T, Arikawa T, Suzuki H, Toyoda S, kikuchi M, Hata Y, Abe S, Taguchi I, Shimamoto K. K201 improves norepinephrine-induced diastolic dysfunction with preserved ejection fraction. Drug Dev Res 2006; 67: 852-861